Insider Selling: Sana Biotechnology, Inc. (NASDAQ:SANA) Insider Sells 290,912 Shares of Stock

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) insider Fmr Llc sold 290,912 shares of the company's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sana Biotechnology Stock Down 14.9 %

Shares of NASDAQ SANA traded down $0.64 during midday trading on Friday, reaching $3.66. 29,449,545 shares of the company's stock traded hands, compared to its average volume of 37,360,465. The stock's 50 day simple moving average is $2.40 and its 200-day simple moving average is $4.06. Sana Biotechnology, Inc. has a one year low of $1.52 and a one year high of $12.00. The company has a market cap of $817.16 million, a price-to-earnings ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. Equities analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SANA shares. HC Wainwright boosted their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Wednesday. TD Cowen raised shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday. Finally, JMP Securities cut shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $14.25.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology in the third quarter valued at approximately $29,000. Stifel Financial Corp acquired a new stake in Sana Biotechnology in the third quarter valued at approximately $43,000. EP Wealth Advisors LLC purchased a new position in shares of Sana Biotechnology in the third quarter worth $45,000. Blue Trust Inc. raised its holdings in shares of Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock worth $55,000 after buying an additional 12,154 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new position in shares of Sana Biotechnology in the third quarter worth $67,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.